Just days be­fore pre­sent­ing at ASH con­fer­ence, Syn­dax out­lines plan to raise $150M

Syn­dax is bank­ing that up­com­ing clin­i­cal da­ta will be enough to woo in­vestors — to the tune of $150 mil­lion.

The biotech kept it short in its an­nounce­ment Tues­day af­ter­noon, say­ing it is plan­ning to sell $150 mil­lion worth of shares of its stock via a pub­lic of­fer­ing. While no date or ex­act num­ber of shares was giv­en for the of­fer­ing, the biotech not­ed it will be giv­ing un­der­writ­ers 30 days to pur­chase up to an ad­di­tion­al 15% of shares sold in the pub­lic of­fer­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER